An evaluation of the indirect cohort method to estimate the effectiveness of the pneumococcal polysaccharide vaccine

Sarah Moberley, Ross Andrews

    Research output: Contribution to journalArticleResearchpeer-review

    Abstract

    We examined the validity of the indirect cohort method as a rapid assessment tool to estimate pneumococcal polysaccharide vaccine effectiveness (VE). Using evidence from published clinical trials, we reviewed the primary assumption about the appropriateness of the control group underpinning the indirect cohort method, which is that the risk of non-vaccine type invasive pneumococcal disease is equal for vaccinated and unvaccinated participants. We found an absence of evidence to support the non-differential risk assumption
    for non-vaccine type invasive pneumococcal disease occurring among clinical trial participants. In those instances where the design has been utilised, we also note that these typically rely on very small numbers of non-vaccine type invasive pneumococcal disease adding to the concerns as an unreliable comparator. We do not consider the indirect cohort method to be a valid tool for rapid assessment of pneumococcal polysaccharide VE.
    Original languageEnglish
    Pages (from-to)4-6
    Number of pages3
    JournalJournal of Vaccines & Immunization
    Volume2
    Issue number1
    DOIs
    Publication statusPublished - 2014

    Fingerprint

    Pneumococcal Vaccines
    Clinical Trials
    Control Groups

    Cite this

    @article{80c8d03316d14aaab6683340dd3ea1a4,
    title = "An evaluation of the indirect cohort method to estimate the effectiveness of the pneumococcal polysaccharide vaccine",
    abstract = "We examined the validity of the indirect cohort method as a rapid assessment tool to estimate pneumococcal polysaccharide vaccine effectiveness (VE). Using evidence from published clinical trials, we reviewed the primary assumption about the appropriateness of the control group underpinning the indirect cohort method, which is that the risk of non-vaccine type invasive pneumococcal disease is equal for vaccinated and unvaccinated participants. We found an absence of evidence to support the non-differential risk assumptionfor non-vaccine type invasive pneumococcal disease occurring among clinical trial participants. In those instances where the design has been utilised, we also note that these typically rely on very small numbers of non-vaccine type invasive pneumococcal disease adding to the concerns as an unreliable comparator. We do not consider the indirect cohort method to be a valid tool for rapid assessment of pneumococcal polysaccharide VE.",
    author = "Sarah Moberley and Ross Andrews",
    year = "2014",
    doi = "10.14312/2053-1273.2014-1",
    language = "English",
    volume = "2",
    pages = "4--6",
    journal = "Journal of Vaccines & Immunization",
    issn = "2053-1273",
    publisher = "NobleResearch Publishers",
    number = "1",

    }

    An evaluation of the indirect cohort method to estimate the effectiveness of the pneumococcal polysaccharide vaccine. / Moberley, Sarah; Andrews, Ross.

    In: Journal of Vaccines & Immunization, Vol. 2, No. 1, 2014, p. 4-6.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - An evaluation of the indirect cohort method to estimate the effectiveness of the pneumococcal polysaccharide vaccine

    AU - Moberley, Sarah

    AU - Andrews, Ross

    PY - 2014

    Y1 - 2014

    N2 - We examined the validity of the indirect cohort method as a rapid assessment tool to estimate pneumococcal polysaccharide vaccine effectiveness (VE). Using evidence from published clinical trials, we reviewed the primary assumption about the appropriateness of the control group underpinning the indirect cohort method, which is that the risk of non-vaccine type invasive pneumococcal disease is equal for vaccinated and unvaccinated participants. We found an absence of evidence to support the non-differential risk assumptionfor non-vaccine type invasive pneumococcal disease occurring among clinical trial participants. In those instances where the design has been utilised, we also note that these typically rely on very small numbers of non-vaccine type invasive pneumococcal disease adding to the concerns as an unreliable comparator. We do not consider the indirect cohort method to be a valid tool for rapid assessment of pneumococcal polysaccharide VE.

    AB - We examined the validity of the indirect cohort method as a rapid assessment tool to estimate pneumococcal polysaccharide vaccine effectiveness (VE). Using evidence from published clinical trials, we reviewed the primary assumption about the appropriateness of the control group underpinning the indirect cohort method, which is that the risk of non-vaccine type invasive pneumococcal disease is equal for vaccinated and unvaccinated participants. We found an absence of evidence to support the non-differential risk assumptionfor non-vaccine type invasive pneumococcal disease occurring among clinical trial participants. In those instances where the design has been utilised, we also note that these typically rely on very small numbers of non-vaccine type invasive pneumococcal disease adding to the concerns as an unreliable comparator. We do not consider the indirect cohort method to be a valid tool for rapid assessment of pneumococcal polysaccharide VE.

    U2 - 10.14312/2053-1273.2014-1

    DO - 10.14312/2053-1273.2014-1

    M3 - Article

    VL - 2

    SP - 4

    EP - 6

    JO - Journal of Vaccines & Immunization

    JF - Journal of Vaccines & Immunization

    SN - 2053-1273

    IS - 1

    ER -